Status | Study |
RECRUITING |
Study Name: Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer Condition: Merkel Cell Carcinoma Date: 2022-10-12 Interventions: Pembrolizumab 400mg IV |
RECRUITING |
Study Name: Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2022-08-08 Interventions: 400mg IV |
Available |
Study Name: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) Condition: Metastatic Merkel Cell Carcinoma Date: 2017-03-20 Interventions: Drug: Avelumab Avelumab should be administered intravenously as per the recommended dose. Administration |
Recruiting |
Study Name: Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Skin Cancer Date: 2017-03-01 Interventions: Drug: Nivolumab Nivolumab 240 |
Not yet recruiting |
Study Name: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Condition: Adenoid Cystic Carcinoma Adnexal Carcinoma Apocrine Carcin Date: 2016-11-30 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Condition: Melanoma Merkel Cell Carcinoma Date: 2016-06-28 Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC) Radi |
Recruiting |
Study Name: Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Polyomavirus Infection Stage IV Merkel Cell Carcinoma Date: 2015-10-21 Interventions: Drug: Avelumab Given IV |
Recruiting |
Study Name: MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2015-07-28 Interventions: Drug: MLN0128 Investigational mTOR kinase inhibitor |
Recruiting |
Study Name: Studies of Dermatologic Diseases Biospecimen Acquisition Protocol Condition: Dermatologic Conditions Healthy Volunteers Normal Voluntee Date: 2015-06-12 |
Recruiting |
Study Name: QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Condition: Stage IIIB Merkel Cell Carcinoma Stage IV Date: 2015-06-03 Interventions: Biological: aNK (NK-92) A natural killer cell line recovered from a patient with large granular lymphoma |